Global Liquid Biopsy Market Research Report 2022: Research vs. Clinical Liquid Biopsy / Liquid Biopsy Market by Type of Analyte

DUBLIN, Jan. 14, 2022 /PRNewswire/ — The “The World Liquid Biopsy Market 2021” report has been added to ResearchAndMarkets.com’s offering. While tissue biopsies and imaging techniques remain the current...

DUBLIN, Jan. 14, 2022 /PRNewswire/ — The “The World Liquid Biopsy Market 2021” report has been added to ResearchAndMarkets.com’s offering.

While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care. 

This report contains up-to-date information and useful data points for business planning:

  • Research vs. Clinical Liquid Biopsy
  • The Market for Liquid Biopsy by Region
  • The Market for Liquid Biopsy Market by Type of Analyte
  • The Market for CTC-based Liquid Biopsy
  • The Market for ctDNA-based Liquid Biopsy
  • The Market for EV and Exosome-based Liquid Biopsy
  • The Market for Multi-Analyte-based Liquid Biopsy
  • The Market for Other Liquid Biopsy
  • Liquid Biopsy Market by Type of Cancer (Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, Other Cancer)
  • Selected ctDNA-based Liquid Biopsy Tests in Development
  • Selected Market-Available CTC-based Liquid Biopsy Tests, 2021
  • Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021

Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:

  • Early detection and diagnosis/screening
  • Alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown
  • Therapy personalization and monitoring – by molecular characterization of a patient’s disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise
  • Disease monitoring – to observe disease progression, tumor evolution, residual disease, and early detection of recurrence
  • Prognosis of disease

Key Topics Covered:

CHAPTER 1: EXECUTIVE SUMMARY

INTRODUCTION

LIQUID BIOPSY TECHNOLOGIES

INDUSTRY STRUCTURE

LIQUID BIOPSY MARKET REVENUES AND FORECAST

CHAPTER 2: LIQUID BIOPSY TECHNOLOGIES

INTRODUCTION

CURRENT MAJOR LIQUID BIOPSY TECHNOLOGIES

CHAPTER 3: CIRCULATING TUMOR DNA (CTDNA) LIQUID BIOPSY

INTRODUCTION

ADVANTAGES AND LIMITATIONS OF CTDNA IN LIQUID BIOPSY

CURRENT CTDNA-BASED LIQUID BIOPSY TESTS

  • Biocartis
  • Biocept
  • Biodesix
  • CellMax Life
  • Circulogene
  • Diacarta
  • Epigenomics
  • Foundation Medicine (Roche)
  • Guardant Health
  • Inivata (Neogenomics)
  • LungLife AI
  • Myriad Genetics
  • NeoGenomics
  • OncoDNA
  • Personal Genomic Diagnostics
  • QIAGEN
  • Resolution Biosciences
  • Roche Diagnostics
  • Sysmex-Inostics
  • Tempus

CTDNA-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT

  • Exact Sciences
  • Freenome
  • GRAIL
  • Neogenomics

CHAPTER 4: CIRCULATING TUMOR CELLS (CTCS) LIQUID BIOPSY

INTRODUCTION

CHALLENGES IN THE DEVELOPMENT OF CTC-BASED LIQUID BIOPSY TESTS

CTC-BASED LIQUID BIOPSY TESTS

  • Adaptive Biotechnologies
  • Biocept
  • CellMax Life
  • Epic Sciences
  • GILUPI
  • LungLife AI
  • Menarini-Silicon Biosystems
  • QIAGEN

CTC-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT

ANGLE

Epic Sciences

Liquid Biotech USA

CHAPTER 5: EXTRACELLULAR VESICLES AND OTHER LIQUID BIOPSY

INTRODUCTION

LIQUID BIOPSY TESTS BASED ON EXTRACELLULAR VESICLES/OTHER ANALYTES

  • Aspira Women’s Health (formerly Vermillion)
  • Biodesix
  • Exosome Diagnostics
  • Hologic
  • MDxHealth

EXTRACELLULAR VESICLE/OTHER ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT

  • Circulogene
  • OncoCyte
  • Resolution Biosciences
  • VolitionRx

CHAPTER 6: MULTI-ANALYTE LIQUID BIOPSY TESTS

LIQUID BIOPSY TESTS BASED ON MULTIPLE ANALYTES

  • Biocept
  • Biodesix
  • Foundation Medicine (Roche)
  • LungLife AI
  • NeoGenomics
  • OncoDNA

MULTIPLE ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT

  • Exact Sciences
  • Freenome
  • GRAIL
  • LungLife AI

CHAPTER 7: LIQUID BIOPSY TESTS FOR RESEARCH USE ONLY

INTRODUCTION

LIQUID BIOPSY TESTS FOR RESEARCH USE ONLY

  • Agena Bioscience
  • ANGLE
  • DiaCarta
  • Exosome Diagnostics
  • Guardant Health
  • Natera
  • QIAGEN

CHAPTER 8: LIQUID BIOPSY INDUSTRY ANALYSIS

TIERS OF COMPETITION

COMPETITIVE FACTORS

SIGNIFICANT MARKET TRENDS

  • Personalized Medicine
  • Increasing Global Life Expectancy
  • New Liquid Biopsy Products
  • Increasing Accessibility of Genetic Testing
  • Regulatory Hurdles
  • Third-Party Payor Coverage
  • Demonstrated Clinical Utility
  • Incidence Rates of Specific Cancers

COMPETITORS NO LONGER IN THE LIQUID BIOPSY MARKET

CHAPTER 9: LIQUID BIOPSY MARKET

MARKET OVERVIEW

MARKET FORECAST

CHAPTER 10: MARKET BY ANALYTE CIRCULATING TUMOR DNA

CIRCULATING TUMOR CELLS

EXTRACELLULAR VESICLES AND OTHER ANALYTES

MULTIPLE ANALYTES

  • Market Overview
  • Applications
  • Technologies
  • Specimens
  • Revenue Forecast

CHAPTER 11: MARKET BY APPLICATION

THERAPY GUIDANCE AND MONITORING

DIAGNOSIS/SCREENING

DISEASE PROGNOSIS

  • Market Overview
  • Revenue Forecast

CHAPTER 12: MARKET BY CANCER TYPE

BREAST CANCER

COLORECTAL CANCER

LUNG CANCER

OVARIAN CANCER

PROSTATE CANCER

OTHER CANCERS: Including bladder, gastrointestinal, pancreatic, renal, melanoma and hematological malignancies.

  • Market Overview
  • Revenue Forecast

PAN-CANCER TESTS

  • Market Overview
  • Revenue Forecast

CHAPTER 13: LIQUID BIOPSY COMPANY PROFILES

TOP TEN COMPANIES IN THE LIQUID BIOPSY MARKET

Companies Mentioned

  • Adaptive Biotechnologies
  • Agena Bioscience, Inc.
  • Angle, plc
  • Aspira Women’S Health
  • Biocartis Group Nv
  • Biocept, Inc.
  • Biodesix
  • Cellmax Life
  • Circulogene
  • Diacarta, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Exact Sciences
  • Exosome Diagnostics, Inc.
  • Foundation Medicine, Inc. (Roche)
  • Freenome, Inc.
  • Gilupi GmbH
  • Grail (Illumina)
  • Guardant Health, Inc.
  • Hologic
  • Lunglife Ai (Formerly Cynvenio Biosystems)
  • Mdxhealth
  • Menarini-Silicon Biosystems, Spa
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Neogenomics Laboratories, Inc.
  • Oncocyte Corporation
  • Oncodna S.A.
  • Oncimmune
  • Personal Genome Diagnostics
  • Predicineq2 Solutionsqiagen N.V.
  • Cell-Free Dna Technologies
  • Ctc Technologies
  • Exosome and Mirna Technologies
  • Resolution Biosciences (Agilent)
  • Roche Diagnostics
  • Stagezero Life Sciences
  • Sysmex-Inostics, Inc.
  • Tempus
  • Veracyte
  • Volitionrx

For more information about this report visit https://www.researchandmarkets.com/r/9iu3nb

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[email protected]

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Categories
Uncategorized
No Comment

Leave a Reply

*

*

RELATED BY